AMPH — Amphastar Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.34bn
- $2.71bn
- $644.40m
- 97
- 60
- 80
- 93
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 46.5 | 1.1 | 63.3 | 91.4 | 138 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 24.4 | 25.7 | 10.7 | 21.2 | 44.7 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -51.7 | 9.13 | -1.92 | -32.2 | -24.2 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 41.8 | 57.3 | 98 | 89.2 | 184 |
Capital Expenditures | -41.6 | -33.9 | -27.5 | -24 | -38.2 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -8.97 | -2.56 | -1.22 | -8.74 | -611 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Cash from Investing Activities | -50.5 | -36.4 | -28.7 | -32.8 | -649 |
Financing Cash Flow Items | — | -0.106 | -56.2 | -0.407 | -25.1 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -3.78 | -2.25 | -37 | -26.4 | 454 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -12.7 | 19 | 32.1 | 29.7 | -11.8 |